Abstract
A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.
Keywords:
.
MeSH terms
-
Adenocarcinoma / blood*
-
Adenocarcinoma / immunology
-
Adenocarcinoma / pathology
-
Adenocarcinoma of Lung
-
Aged
-
Aged, 80 and over
-
Biomarkers, Tumor / blood*
-
Carcinoma, Non-Small-Cell Lung / blood*
-
Carcinoma, Non-Small-Cell Lung / immunology
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Squamous Cell / blood*
-
Carcinoma, Squamous Cell / immunology
-
Carcinoma, Squamous Cell / pathology
-
Case-Control Studies
-
Cell Adhesion
-
Computational Biology
-
Databases, Protein
-
Diagnosis, Differential
-
Female
-
Humans
-
Lung Neoplasms / blood*
-
Lung Neoplasms / immunology
-
Lung Neoplasms / pathology
-
Lymphocytes / immunology
-
Lymphocytes / metabolism
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Phenotype
-
Predictive Value of Tests
-
Proteomics / methods*
-
Tandem Mass Spectrometry*